Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants

Journal of Infectious Diseases

Volumn 174, Issue 6, 1996, Pages 1360-1363

  Fairley, Christopher K ^a   Begg, Norman ^b   Borrow, Raymond ^b   Fox, Andrew J ^b   Jones, Dennis M ^b   Cartwright, Keith ^b  

^a ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; UNITED KINGDOM; VACCINATION;

EID: 0029852070     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.6.1360     Document Type: Article

References (15)

1. Jones DM, Kaczmarski EB. Meningococcal infections in England and Wales: 1994. Commun Dis Rep CDR Rev 1995;5:R125-30.
2. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich E. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60:673-80.
3. Granoff DM, Holmes SJ, Osterblom MT, et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993;168:663-71.
4. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62:3391-5.
5. Twumasi PA, Kumah S, Leach A, et al. A trial of group A and group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171:632-8.
6. Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococci A and C. Vaccine 1992;10:691-8.
7. Centers for Disease Control. Report of the second International Workshop on Meningococcal Immunology and Serology, 17-18 June 1992 (Decatur, GA). Atlanta: CDC, 1992.
8. Holder PK, Maslanksa SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC 1992. Clin Diagn Lab Immunol 1995;2:132-7.
9. Goldschneider I, Lepow ML, Gotschlich EC, Mauck FT, Bachl F, Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis 1973;128:769-76.
10. Taunay AE, de Glavao PA, de Morais JA, Gotschlich EC, Feldman RA. Disease prevention by meningococcal serogroup C polysaccharide vaccine in preschool children: results after 11 months in Sao Paulo, Brazil [abstract]. Pediatr Res 1974;8:429.
11. Fairley CK, White JM, Begg NT. Fast-tracking meningococcal vaccination. Lancet 1994;344:1164-5.
12. Peltola H, Mäkelä PH, Käyhty H, et al. Clinical efficacy of meningococcus serogroup A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977;297:686-91.
13. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
14. Weinberg G, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. Immunological priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b pplysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. J Pediatr 1987;111:22-7.
15. Gold R. Immunogenicity of meningococcal polysaccharide in man. In: Rudbach J, Baker P, eds. Immunology of bacterial polysaccharides. New York: Elsevier, 1979:121-51.